Cargando…
Therapeutic Potential of the Cyclin-Dependent Kinase Inhibitor Flavopiridol on c-Myc Overexpressing Esophageal Cancer
Tumors with elevated c-Myc expression often exhibit a highly aggressive phenotype, and c-Myc amplification has been shown to be frequent in esophageal cancer. Emerging data suggests that synthetic lethal interactions between c-Myc pathway activation and small molecules inhibition involved in cell cy...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8490822/ https://www.ncbi.nlm.nih.gov/pubmed/34621175 http://dx.doi.org/10.3389/fphar.2021.746385 |
_version_ | 1784578603889983488 |
---|---|
author | Hassan, Md Sazzad Cwidak, Nicholas Johnson, Chloe Däster, Silvio Eppenberger-Castori, Serenella Awasthi, Niranjan Li, Jun Schwarz, Margaret A. von Holzen, Urs |
author_facet | Hassan, Md Sazzad Cwidak, Nicholas Johnson, Chloe Däster, Silvio Eppenberger-Castori, Serenella Awasthi, Niranjan Li, Jun Schwarz, Margaret A. von Holzen, Urs |
author_sort | Hassan, Md Sazzad |
collection | PubMed |
description | Tumors with elevated c-Myc expression often exhibit a highly aggressive phenotype, and c-Myc amplification has been shown to be frequent in esophageal cancer. Emerging data suggests that synthetic lethal interactions between c-Myc pathway activation and small molecules inhibition involved in cell cycle signaling can be therapeutically exploited to preferentially kill tumor cells. We therefore investigated whether exploiting elevated c-Myc expression is effective in treating esophageal cancer with the CDK inhibitor flavopiridol. We found frequent overexpression of c-Myc in human esophageal cancer cell lines and tissues. c-Myc overexpression correlated with accelerated esophageal cancer subcutaneous xenograft tumor growth. Esophageal cancer cells with elevated c-Myc expression were found preferentially more sensitive to induction of apoptosis by the CDK inhibition flavopiridol compared to esophageal cancer cells with lower c-Myc expression. In addition, we observed that flavopiridol alone or in combination with the chemotherapeutic agent nanoparticle albumin-bound paclitaxel (NPT) or in combinations with the targeted agent BMS-754807 significantly inhibited esophageal cancer cell proliferation and subcutaneous xenograft tumor growth while significantly enhancing overall mice survival. These results indicate that aggressive esophageal cancer cells with elevated c-Myc expression are sensitive to the CDK inhibitor flavopiridol, and that flavopiridol alone or in combination can be a potential therapy for c-Myc overexpressing esophageal cancer. |
format | Online Article Text |
id | pubmed-8490822 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84908222021-10-06 Therapeutic Potential of the Cyclin-Dependent Kinase Inhibitor Flavopiridol on c-Myc Overexpressing Esophageal Cancer Hassan, Md Sazzad Cwidak, Nicholas Johnson, Chloe Däster, Silvio Eppenberger-Castori, Serenella Awasthi, Niranjan Li, Jun Schwarz, Margaret A. von Holzen, Urs Front Pharmacol Pharmacology Tumors with elevated c-Myc expression often exhibit a highly aggressive phenotype, and c-Myc amplification has been shown to be frequent in esophageal cancer. Emerging data suggests that synthetic lethal interactions between c-Myc pathway activation and small molecules inhibition involved in cell cycle signaling can be therapeutically exploited to preferentially kill tumor cells. We therefore investigated whether exploiting elevated c-Myc expression is effective in treating esophageal cancer with the CDK inhibitor flavopiridol. We found frequent overexpression of c-Myc in human esophageal cancer cell lines and tissues. c-Myc overexpression correlated with accelerated esophageal cancer subcutaneous xenograft tumor growth. Esophageal cancer cells with elevated c-Myc expression were found preferentially more sensitive to induction of apoptosis by the CDK inhibition flavopiridol compared to esophageal cancer cells with lower c-Myc expression. In addition, we observed that flavopiridol alone or in combination with the chemotherapeutic agent nanoparticle albumin-bound paclitaxel (NPT) or in combinations with the targeted agent BMS-754807 significantly inhibited esophageal cancer cell proliferation and subcutaneous xenograft tumor growth while significantly enhancing overall mice survival. These results indicate that aggressive esophageal cancer cells with elevated c-Myc expression are sensitive to the CDK inhibitor flavopiridol, and that flavopiridol alone or in combination can be a potential therapy for c-Myc overexpressing esophageal cancer. Frontiers Media S.A. 2021-09-21 /pmc/articles/PMC8490822/ /pubmed/34621175 http://dx.doi.org/10.3389/fphar.2021.746385 Text en Copyright © 2021 Hassan, Cwidak, Johnson, Däster, Eppenberger-Castori, Awasthi, Li, Schwarz and von Holzen. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Hassan, Md Sazzad Cwidak, Nicholas Johnson, Chloe Däster, Silvio Eppenberger-Castori, Serenella Awasthi, Niranjan Li, Jun Schwarz, Margaret A. von Holzen, Urs Therapeutic Potential of the Cyclin-Dependent Kinase Inhibitor Flavopiridol on c-Myc Overexpressing Esophageal Cancer |
title | Therapeutic Potential of the Cyclin-Dependent Kinase Inhibitor Flavopiridol on c-Myc Overexpressing Esophageal Cancer |
title_full | Therapeutic Potential of the Cyclin-Dependent Kinase Inhibitor Flavopiridol on c-Myc Overexpressing Esophageal Cancer |
title_fullStr | Therapeutic Potential of the Cyclin-Dependent Kinase Inhibitor Flavopiridol on c-Myc Overexpressing Esophageal Cancer |
title_full_unstemmed | Therapeutic Potential of the Cyclin-Dependent Kinase Inhibitor Flavopiridol on c-Myc Overexpressing Esophageal Cancer |
title_short | Therapeutic Potential of the Cyclin-Dependent Kinase Inhibitor Flavopiridol on c-Myc Overexpressing Esophageal Cancer |
title_sort | therapeutic potential of the cyclin-dependent kinase inhibitor flavopiridol on c-myc overexpressing esophageal cancer |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8490822/ https://www.ncbi.nlm.nih.gov/pubmed/34621175 http://dx.doi.org/10.3389/fphar.2021.746385 |
work_keys_str_mv | AT hassanmdsazzad therapeuticpotentialofthecyclindependentkinaseinhibitorflavopiridoloncmycoverexpressingesophagealcancer AT cwidaknicholas therapeuticpotentialofthecyclindependentkinaseinhibitorflavopiridoloncmycoverexpressingesophagealcancer AT johnsonchloe therapeuticpotentialofthecyclindependentkinaseinhibitorflavopiridoloncmycoverexpressingesophagealcancer AT dastersilvio therapeuticpotentialofthecyclindependentkinaseinhibitorflavopiridoloncmycoverexpressingesophagealcancer AT eppenbergercastoriserenella therapeuticpotentialofthecyclindependentkinaseinhibitorflavopiridoloncmycoverexpressingesophagealcancer AT awasthiniranjan therapeuticpotentialofthecyclindependentkinaseinhibitorflavopiridoloncmycoverexpressingesophagealcancer AT lijun therapeuticpotentialofthecyclindependentkinaseinhibitorflavopiridoloncmycoverexpressingesophagealcancer AT schwarzmargareta therapeuticpotentialofthecyclindependentkinaseinhibitorflavopiridoloncmycoverexpressingesophagealcancer AT vonholzenurs therapeuticpotentialofthecyclindependentkinaseinhibitorflavopiridoloncmycoverexpressingesophagealcancer |